Clinical characteristics of paediatric neuro- XXXX : a single tertiary centre experience.

@entity1 @entity66 @entity16 @entity134 @entity195 @entity10 @entity50 @entity5576
OBJECTIVES: To investigate the demographic and neurological features and treatment modalities of neuro- @entity195 ( @entity66 ) in @entity1 , to share our experiences and to summarise the literature. METHODS: We retrospectively reviewed the medical records of @entity195 ( @entity195 ) @entity1 who attended our paediatric rheumatology department between December 2005 and October 2013. Five @entity1 had the diagnosis of @entity66 . Initial neurological presentation, clinical @entity195 presentation, magnetic resonance imaging pictures of those five @entity1 was recorded. RESULTS: A total of 18 @entity1 were diagnosed with @entity195 . Among @entity195 @entity1 five of them were identified with @entity66 (27.8%). The mean age of @entity66 @entity1 at the time of diagnosis was 12.4 years (range 5.5-15 years). The mean follow-up time after the @entity16 was 5.2 years (range 0.5-14). In two cases @entity16 occurred at the same time with the onset of other clinical findings of @entity195 (40%). Both of these @entity1 had parenchymal involvement. Three @entity1 were admitted with @entity10 as the initial neurological symptom. They revealed @entity5576 . One of them had @entity50 ( @entity50 ). The other two had normal cranial magnetic resonance imagines. All @entity1 received colchicine and @entity134 , two of them who had parenchymal involvement received also cytotoxic drugs. CONCLUSIONS: This study has shown that neurological symptoms can be the first manifestations of @entity195 in @entity1 . Clinicians should be aware of this possibility and when a @entity1 presents with neurological manifestations, it would be valuable to query the @entity1 for the clinical features of @entity195 .
